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ABSTRACT 
7 
 
Autologous platelet concentrates have been extensively used in a variety of 
medical fields to promote hard and soft tissue regeneration. The significance 
behind their use lies in the abundance of growth factors in platelets α-
granules that promotes wound healing. In addition, antibacterial properties of 
platelet concentrates have been recently pointed out. 
In this study, the antimicrobial effect of pure platelet-rich plasma (P-PRP) was 
evaluated against microorganisms isolated from oral cavity, such as Candida 
albicans, Enterococcus faecalis, Pseudomonas aeruginosa, Streptococcus 
agalactiae and Streptococcus oralis. The effect of the platelet concentration, 
of the CaCl2 activation step and of the presence of plasmatic components on 
the antimicrobial activity of P-PRP was also investigated. 
Blood samples were obtained from healthy donors. The antibacterial activity 
of P-PRP, evaluated as the minimum inhibitory concentration, was 
determined through the microdilution two-fold serial method. 
Results showed that P-PRP was able to inhibit the growth of E. faecalis, C. 
albicans, S. agalactiae and S. oralis, but not of P. aeruginosa strains. The 
antimicrobial activity of P-PRP seemed to be sustained by a co-operation of 
plasma components and platelet-derived factors. Moreover, the activation of 
coagulation with CaCl2 appeared to represent a fundamental step for the 
antibacterial activity of P-PRP. 
The antimicrobial properties of P-PRP might represent a valuable adjunct to 
the enhancement of tissue regeneration.  
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1. INTRODUCTION 
 
 
 
 
 
9 
 
1.1. Platelets 
Besides red blood cells, platelets are the second anuclear blood 
compartment. They play a crucial role in primary hemostasis, as well as in a 
variety of other physiological processes. To fulfill these functions, they 
contain a variety of mediators, which are stored in intracellular vesicles or 
granules. In this chapter, the biology and function of platelets will be 
discussed in detail. 
 
1.1.1. Platelet biology 
Platelets are small anucleate cell fragments that originate from 
megakaryocytes in the bone marrow. Megakaryocyte and platelet production 
is regulated by thrombopoietin, a hormone produced mainly by liver and 
kidneys. Each megakaryocyte gives rise to 5.000-10.000 platelets. An 
average healthy adult produces around 1011 platelets per day. The 
physiological platelet concentration in whole blood is 150.000-400.000/µl. If 
the number of platelets is too low, excessive bleeding can occur; if the 
number of platelets is too high, blood clots can form and obstruct 
vessels. Reserve platelets are stored in the spleen and released when 
needed by sympathetically-induced splenic contraction. The lifespan of 
circulating platelets is 5-9 days. Old platelets are destroyed 
by phagocytosis in the spleen and in the liver. 
 
1.1.1.1. Platelet formation 
Platelets originate from the cytoplasm of megakaryocytes, their precursor 
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cells, which reside in the bone marrow.(1) Megakaryocytes are the largest 
(50–100 μm) and one of the rarest cells in the bone marrow; they account for 
about 0,01% of nucleated bone marrow cells.(2) They are highly specialized 
precursor cells that function solely to produce and release platelets into the 
circulation. To assemble and release platelets, megakaryocytes become 
polyploid by endomitosis (DNA replication without cell division) and then 
undergo a maturation process in which the bulk of their cytoplasm is 
packaged into multiple long processes called proplatelets, and the nucleus is 
extruded. A megakaryocyte may extend 10–20 proplatelets, each starting as 
a blunt protrusion that over time elongates, thins, and branches repeatedly. 
Platelets form selectively at the tips of proplatelets.(3) As platelets develop, 
they receive their granule and organelle content as streams of individual 
particles transported from the megakaryocyte cell body.(4) Platelet formation 
can be arbitrarily divided into two phases. The first phase of megakaryocyte 
maturation and development takes days to complete and requires 
megakaryocyte-specific growth factors. During this time, massive nuclear 
proliferation and enlargement of the megakaryocyte cytoplasm occur as the 
cell is filled with cytoskeletal proteins, platelet-specific granules and sufficient 
membrane to complete the platelet assembly process. The second phase is 
relatively rapid and can be completed within hours. During this phase, 
megakaryocytes generate platelets by remodeling their cytoplasm first into 
proplatelets and then into preplatelets, which undergo subsequent fission 
events to generate discoid platelets (Figure 1). The time required for 
megakaryocytes to complete polyploidization, mature, and release platelets 
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is about 5 days in humans.(5-7)  
 
 
Figure 1. Megakaryocytes transition from immature cells (A) to released 
platelets (E). From Thon and Italiano, Semin Hematol 2010; 47:220–226. 
 
1.1.1.2. Platelet structure 
Platelets are small anucleate cell fragments that have a characteristic discoid 
shape and range from 1 to 3 μm in diameter (Figure 2). The platelet cell can 
be divided into a) a peripheral zone (glycocalyx, plasma membrane, 
submembrane area), b) a sol-gel zone (microtubules, microfilaments, 
glycogen, smooth and coated vesicles), c) an organelle zone (α-granules, 
dense bodies, electron-dense chains and clusters, lysosomes, glycosomes, 
tubular inclusions, mitochondria) and d) membrane systems (Golgi 
complexes, surface-connected open canalicular system, dense tubular 
system, membrane complexes). 
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Figure 2. Discoid platelet (a), dendritic platelet (b) and spread platelet 
(c) photographed in the low-voltage, high-resolution scanning electron 
microscope. Magnification 30.000X, 13.000X and  11.000X. From 
Michelson, Platelets (Second Edition) 2006; p 46. 
 
a) Peripheral zone 
Platelet plasma membrane has a thick external coat called glycocalyx. This 
coating consists of the carbohydrate moieties of membrane glycolipids and 
glycoproteins. Glycoproteins play a role in platelet adhesion to damaged 
surfaces, platelet  activation, aggregation and interaction with other cells.(8, 
9) The main glycoproteins involved in hemostasis are the glycoprotein (GP) 
Ib-IX-V complex and the integrin αIIbβ3 (GP IIb-IIIa complex) (Figure 3). 
The phospolipid bilayer of the plasma membrane is morphologically similar to 
that of the membranes covering other cells.  
The area lying just below the plasma membrane is important to platelet 
function. Here the cytoplasmic domains of transmembrane receptors interact 
with proteins regulating the signaling processes of platelet activation. Many of 
these proteins are associated with calmodulin, myosin and short actin 
filaments making up the membrane contractile cytoskeleton.(10, 11) The 
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contractile system of this area is involved in platelet shape changes and in 
the translocation of receptor complexes to the platelet outer surface, both 
critical processes for cellular adhesion and spreading at sites of vascular 
injury. 
 
 
Figure 3. Schematic representation of platelet structure. From Anitua et 
al., Thromb Haemost 2004;91:4–15. 
 
b) Sol-gel zone 
In addition to the subsurface membrane contractile filament system 
discussed earlier, two other filament systems are present in platelet 
cytoplasm. One is the circumferential coil of microtubules, which is the major 
cytoskeletal support system responsible for maintaining the discoid shape of 
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platelets.(12, 13) The other is the actomyosin filament system, that serves as 
the matrix on which organelles and other structural components are 
suspended and maintained separate from each other and the cell wall in 
resting cells.(14) Following platelet activation, the cytoplasmic actomyosin 
cytoskeleton constricts the circumferential coil of microtubules and drives α-
granules and dense bodies into close association in platelet centers.(15) If 
stimulation is strong enough, α-granules and dense body contents are 
secreted to the exterior of the cell via channels of the surface-connected 
open canalicular system (OCS).(14, 16) The cytoplasmic actomyosin 
cytoskeleton is also involved in shape changes, hemostatic plug contraction 
and clot retraction. 
Glycogen particles and smooth and coated vesicles are randomly distributed 
in platelet cytoplasm.(17-19) Their origin and function are unknown.  
 
c) Organelle zone 
Platelets contain three major types of secretory organelles: α-granules, 
dense bodies and lysosomes. Occasional multivesicular bodies (MVBs) are 
also present. MVBs develop in megakaryocytes by the fusion of small 
vesicles budding from the trans-Golgi network (TGN) and serve as sorting 
stations in the development of α granules, dense bodies, and lysosomes.(20) 
Among platelet granules, α-granules are the most abundant. There are 
approximately 50-80 α-granules per platelet, ranging in size from 200 to 500 
nm.(21) The development of α-granules takes place in megakaryocytes.(22) 
α-granules cargo derives from budding of the TGN and from endocytosis of 
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the plasma membrane, both clathrin-mediated processes; pinocytosis of 
cargo can also occur. Vesicles are subsequently delivered to MBVs, where 
sorting occurs. MVBs then mature to produce α-granules (Figure 4a).(17, 23, 
24) During platelet formation, α-granules are transported along microtubules 
from the megakaryocyte cell body through proplatelets (Figure 4b). Platelets 
form as bulges along the length of these extensions and α-granules are 
maintained in the nascent platelets by coiled microtubules.(25, 26) α-granule 
content is released when the vescicle membrane fuses with surface-
connected membranes of the OCS or with the plasma membrane.(27) 
SNAREs represent the core of the fusion machinery. Coiled-coil domains 
within vesicle (v-SNAREs) and target SNAREs (t-SNAREs) interact, forming 
a twisted 4-helical bundle, bringing the opposing membranes of granule and 
cell into close apposition. Binding of vSNAREs and tSNAREs generates 
energy required for membrane fusion. Pore formation with release of granule 
contents subsequently ensues (Figure 4c).(28, 29) α-granules appear to be 
heterogeneous with regard to cargo.(30, 31) Hundreds of bioactive proteins, 
playing roles in various biological functions, are released from α-granules. 
Such molecules will be discussed in detail later. 
Dense bodies are smaller and fewer than α-granules.(32) They are rich in 
ADP, ATP, Ca2+, serotonin and histamine. ADP promotes platelet aggregation 
while ATP participates in platelet response to collagen. Ca2+ is a necessary 
cofactor for platelet aggregation and fibrin formation. Serotonin release leads 
to vasoconstriction and increased capillary permeability. Histamine can have 
pro- and anti-inflammatory effects.(33) 
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Platelets also contain few lysosomes, which can secrete acid hydrolases, 
cathepsins D and E, elastase and other degradative enzymes.(34) 
Small numbers of relatively simple mitochondria are present in the platelet 
cytoplasm. They serve an important role in energy metabolism.(35) Other 
membrane-enclosed organelles or structures are also present in the cell, 
such as glycosomes, electron-dense chains and clusters(36), and tubular 
inclusions.(19, 36, 37) Their origin and function is unknown. 
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Figure 4. α-granules formation in megakaryocytes (a), transport during 
proplatelet formation (b) and degranulation in mature platelets (c). 
Adapted from Blair & Flaumenhaft, Blood Reviews 2009;23:177–189. 
 
d) Platelet membrane system 
Golgi complexes are membrane systems ordinarily confined to 
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megakaryocytes. However, residual membrane elements of the Golgi 
apparatus, consisting of a few parallel-associated, flattened sacules with no 
budding vesicles, are found in less than 1% of circulating platelets.(38) 
The OCS is part of the platelet surface membrane.(39-41) OCS channels are 
tortuous invaginations of surface membrane tunneling through the cytoplasm 
in a serpentine manner. Channels of the OCS greatly expand the total 
surface area of the platelet exposed to circulating plasma and provide a 
means for chemical and particulate substances to reach the deepest 
recesses of the cell.(42, 43) As a result, the OCS may be the major route for 
the uptake and transfer of products from plasma granules and serve as 
conduit for the discharge of products stored in secretory organelles.(44-46)  
Channels of the OCS have also major roles in the hemostatic reaction. After 
adhesion to a damaged vascular surface, the platelet extends filopodia to 
bind firmly to the injured area. This is followed rapidly by the assembly of 
cytoplasmic actin filaments and by the spreading of the platelet to cover as 
much area as possible. The result is an increase of up to 420% of the 
exposed surface area during conversion from a discoid platelet to a fully 
spread cell. Evaginated channels of the OCS are the major source of 
membrane for the expanded surface area of the spread platelet.(47)  
Channels of the dense tubular system (DTS) are randomly dispersed in 
platelet cytoplasm.(39) They represent residual smooth endoplasmic 
reticulum of the parent cell. 
OCS and DTS are not completely isolated membrane systems. Canaliculi of 
the OCS and DTS form intimate physical relationships in nearly every 
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cell.(48) 
The rarest of the membrane systems found in circulating platelets is rough 
endoplasmic reticulum (RER). The RER in the parent megakaryocyte has 
disappeared by the time granulopoiesis has been completed and before 
proplatelets are formed. Platelets RER channels are usually in parallel 
association. Ribosomal complexes are also present in cytoplasm adjacent to 
the RER.(49) 
 
1.1.2. Functional roles  
Platelets are known for their role in hemostasis, where they help prevent 
blood loss at sites of vascular injury. Yet, increasing evidence indicates that 
platelets fulfill a much wider role in health and disease. In fact, platelets are 
also involved in the modulation of innate immune response, inflammation, 
angiogenesis, wound healing and in the pathogenesis of various diseases 
(e.g. atherosclerosis, Alzheimer’s disease and cancer) (Figure 5). The role 
played by platelets in hemostasis, wound healing and antimicrobial host 
defense will be discussed in the following paragraphs. 
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Figure 5. Role of platelets in hemostasis and other functions. From 
Nurden, Thromb Haemost 2011;105 Suppl 1:S13-33. 
 
1.1.2.1. Hemostasis 
Much is known about how platelets fulfill their function in hemostasis. After 
disruption of the integrity of the endothelial cell lining of a blood vessel, 
circulating platelets localize, amplify and sustain the coagulant response at 
the injured site. Platelets provide the first line of defense in plugging the leaky 
vessel by adhering to the site of injury. Platelet adhesion and activation are 
mediated primarily by their interactions with the subendothelial proteins von 
Willebrand factor (vWf) and collagen. Platelets bind to subendothelial vWf 
primarily via the platelet membrane glycoprotein GPIb-IX-V complex and to 
collagen via the integrin α2β1 and GPVI.(50-52) Platelet adherence to 
collagen via GPVI triggers the intracellular signaling events that result in 
platelet activation.(53-55) One platelet activation event, platelet aggregation, 
serves to prevent additional blood loss from a damaged vessel in the earliest 
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stage of hemostasis. Platelet aggregation is a result of the cross-linking of 
activated integrin αIIbβ3 (GPIIb-IIIa) molecules expressed on the surface of 
two different platelets by fibrinogen to form a temporary platelet plug that 
prevents additional blood loss from the leaky vessel.(56) Platelet adherence 
and aggregation at a site of vascular injury serve not only to plug the 
damaged vessel temporarily, but also to localize subsequent procoagulant 
events to the injured site to prevent systemic activation of coagulation. 
Furthermore, activated platelets actively regulate the propagation of the 
coagulation reaction by releasing a number of bioactive peptides and small 
molecules from their α- and dense granules that recruit additional platelets to 
the growing thrombus, as well as participate directly in procoagulant events. 
Whereas platelet dense granules contain high concentrations of low 
molecular weight compounds that potentiate platelet activation (e.g., ADP, 
serotonin, calcium), α-granules concentrate large polypeptides that contribute 
to both primary and secondary hemostasis. α-granules secrete: 
 adhesive proteins (e.g. fibrinogen, vWf) which mediate platelet–
platelet and platelet–endothelial interactions;(57, 58) 
 adhesive receptors (e.g. GPIbα-IX-V, GPVI, integrin αIIbβ3) that also 
participate in platelet adhesion;(59, 60) 
 coagulation factors and co-factors (e.g. factor V, XI, XIII, prothrombin, 
high molecular weight kininogens) which participate in secondary 
hemostasis;(61-65)   
 proteins that contribute to hemostatic balance by limiting the 
progression of coagulation (e.g. antithrombin, C1-inhibitor, tissue factor 
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pathway inhibitor, protein S, protease nexin-2, plasmin and 
plasminogen).(66-68) 
This overall process provides for rapid fibrin polymerization at the wound site, 
transforming blood in the fluid phase to a solid phase plug. 
 
1.1.2.2. Wound healing 
Platelets are crucial for vascular remodeling and tissue repair.(69) Platelet 
proteomes are extremely complex.(70, 71) Activated platelets release, or 
expose at their surface, biologically active molecules that promote the 
recruitment, growth, and differentiation of cells. Platelet bioactive substances 
are entrapped within α-granules, dense granules and lysosomal granules, or 
are present in the cytoplasm. Growth factors that are mostly contained within 
α-granules are key factors orchestrating tissue regeneration. Growth factors 
act binding to specific receptors on the cell membrane; a second messenger 
transmits the signal into the cell, eliciting a physiological response (Figure 6). 
The role played by platelet growth factors in hard and soft tissue regeneration 
will be discussed in detail later. 
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Figure 6. Growth factors’ signalling pathway. Adapted from Chau et al., 
Histol Histopathol 2009;24:1593-1606. 
 
1.1.2.3. Antimicrobial host defense 
Platelets play a significant role in host defense against pathogenic 
microorganisms.(72, 73) Numerous studies have demonstrated that platelets 
are among the first blood cells to recognize endothelium damaged by 
microbial colonization and to accumulate at sites of infected endovascular 
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lesions.(72, 74) Platelets interact directly with viruses, bacteria, fungi, and 
protozoa.(75-77) Platelet α-granules contain proteins with direct microbicidal 
properties, a group collectively referred to as “platelet microbicidal 
proteins”.(78) Many of the chemokines secreted by activated platelets - 
including CXCL4, thymosin-β4, the derivatives of CXCL7 (PBP, CTAP-III, 
NAP-2) and CCL5 (RANTES) – are microbicidal.(79, 80) Truncation of CTAP-
III and NAP-2 at their C-terminus generates two additional peptides, 
thrombocidins-1 and -2, which are bactericidal in vitro against some strains of 
Bacillus subtilis and Staphylococcus aureus, and fungicidal for Cryptococcus 
neoformans.(81) Another microbicidal protein, thymosin-β4, localizes to 
platelet α-granules.(80) While it is debatable whether the local concentration 
of these secreted proteins are more important for antimicrobial activity or 
chemoattraction of leukocytes, multiple studies using combined in vitro and in 
vivo techniques have demonstrated that platelets are clinically relevant to 
host defense.(82, 83) α-granules also contain complement and complement 
binding proteins, which facilitate the clearance of microorganisms from the 
circulation. Platelet α-granules secrete C3 and C4 precursors, which 
participate in the complement activation cascade. P-selectin binds C3b, 
localizing the inflammatory response to sites of vascular injury.(84) Platelets 
α-granules also contain regulators of complement activation, such as C1 
inhibitor.(85) Platelet factor H secreted from α-granules regulates C3 
convertase in the alternative pathway.(86)  
 
1.2. Platelet concentrates 
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As discussed earlier, platelets contain growth factors and other bioactive 
metabolites which are able to stimulate cell chemotaxis, proliferation and 
differentiation. For this reason, they have been adopted in clinical situations 
requiring rapid healing and tissue regeneration. Their administration in the 
form of platelet concentrates provides an adhesive support that can confine 
secretion of such bioactive substances to a chosen site. In this chapter, the 
history, classification, biological effects and therapeutic applications of 
platelet concentrates will be discussed, together with the evidence gathered 
from our previous work. 
 
1.2.1. History of the medical use of platelet concentrates 
The use of blood-derived products to seal wounds and stimulate healing 
started with the use of fibrin glues, which were first described nearly 100 
years ago. Their use is very limited owing to the complexity and the cost of 
their production protocols. Consequently, the use of platelet concentrates to 
improve healing and to replace fibrin glues has been explored considerably 
during the last 20 years. Several types of platelet concentrates were 
developed. They can be basically distinct into two categories: platelet-rich 
plasma (PRP) and platelet-rich fibrin (PRF).  
 
1.2.1.1. Fibrin glue 
Fibrin glue has been studied for decades, originally for its use in surgery as a 
hemostatic agent and a sealant.(87-89) More recently, it has been used as 
carrier for cells, growth factors and drugs in tissue engineering 
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applications.(90-92) Fibrin glue consists of two components, a fibrinogen 
solution and a thrombin solution rich in Ca2
+. When the two components are 
mixed, thrombin cleaves fibrinogen to form fibrin and factor XIII to form factor 
XIIIa, which then crosslinks fibrin to form a gel.(93) The fibrinogen 
component is obtained from pooled human plasma through cryoprecipitation 
and ethanol fractionation.(94) The cryoprecipitation uses a citrate buffer in a 
cold environment to precipitate fibrinogen. The ethanol fractionation method 
precipitates fibrinogen with 10% ethanol. The obtained fibrinogen is then 
lyophilized and sterilized before reconstitution. Initially, a commercial bovine 
enzyme was used for the thrombin component; For safety reasons, 
nowadays human and recombinant thrombin have replaced bovine one in 
commercial products.  
 
1.2.1.2. Platelet-rich plasma  
In transfusion medicine, platelet concentrates were originally used for the 
treatment and prevention of haemorrhage due to severe thrombopenia. The 
standard platelet concentrate for transfusion has been named “platelet-rich 
plasma” (PRP). The use of PRP to improve healing and to replace fibrin 
glues was first described by Whitman et al. in 1997.(95) Several techniques 
for the production of PRP are available. All available techniques have some 
points in common: blood is collected with anticoagulant just before surgery 
and is immediately processed by centrifugation. A first centrifugation step is 
designed to separate the blood into three layers: red blood cells at the 
bottom, platelet-poor plasma (PPP) at the top, and a “buffy coat” layer rich in 
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leukocytes and platelets in the middle. The next steps vary among the 
numerous protocols but are always an attempt to discard erythrocytes and to 
concentrate platelets, including or not leukocytes (Figure 7). Finally, the 
obtained platelet concentrate is applied to the surgical site, together with 
thrombin and/or CaCl2 (or similar factors) to trigger platelet activation and 
fibrin polymerization. Although bovine thrombin has been used by some 
authors, this is now avoided because of the risk of the development of 
antibodies to factors V, XI and thrombin, resulting in the risk of life-
threatening coagulopathies.(96) Human and recombinant thrombin, or CaCl2 
(or similar factors) alone are used instead. Originally, PRP was prepared 
using a plasmapheresis system and required the collection of a large amount 
of blood (up to 500 ml). PRP obtained with this method classically contains 
0,5 x 1011 platelets per unit. Recent centrifuges allow to collect smaller 
amounts of blood (usually about 60 ml) and obtain a lower platelet 
concentration in PRP. In fact, the best results in vitro have been obtained with 
physiological platelet amounts, that is, for a PRP with a platelet concentration 
that was equivalent to 2,5 times the blood concentration.(97) Higher platelet 
concentrations seemed to induce negative effects. However, the data on the 
dose-dependent effects is limited and should be investigated further. 
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Figure 7. Production of PRP.  BC = buffy coat, PPP = platelet-poor plasma, 
RBC = red blood cells. Adapted from Dohan Ehrenfest et al., Trends 
Biotechnol 2009;27:158-167. 
 
1.2.1.3. Platelet-rich fibrin  
PRF was developed by Choukroun et al. in 2001.(98) For the production of 
PRF, blood is collected without any anticoagulants and centrifuged. In the 
absence of anticoagulants, platelet activation and fibrin polymerization are 
triggered immediately. After centrifugation, three layers are formed: red blood 
cells at the bottom, acellular plasma at the top and a PRF clot in the middle 
(Figure 8).(99) The PRF clot is a strong fibrin matrix in which most of the 
platelets and leucocytes are concentrated.(100, 101) Unlike PRP, PRF does 
not dissolve quickly after application, but is slowly remodeled in a similar way 
to a natural blood clot. Platelets are activated during the centrifugation, 
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leading to a substantial embedding of platelet and leukocyte growth factors 
into the fibrin matrix.  
 
 
Figure 8.  Production of PRF. Adapted from Dohan Ehrenfest et al., Trends 
Biotechnol 2009;27:158-167. 
 
1.2.2. Classification 
Nowadays many platelet separation systems that produce distinct types of 
platelet concentrates are available. It would be important to better 
characterize the content of platelet concentrates produced by the various 
commercial systems to make more informed decisions regarding their use in 
the clinical setting. A recent series of letters were published about platelet 
concentrates, where both terminology and content were hotly debated.(102-
106) The definition and classification of platelet concentrates are indeed very 
important issues, as many misunderstandings are widely spread in the 
literature on this topic. Such techniques were initially gathered under the 
name “PRP” in reference to the generic term used in transfusion hematology, 
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but this name is too general for the qualification of the many products 
availabe today. A proposal for terminology and for a wide classification 
system for platelet concentrates has been improved and systematized in two 
recent publications.(107, 108) 
According to Dohan Ehrenfest et al., four main categories of products can be 
defined, depending on their leukocyte content and fibrin architecture: pure 
platelet-rich plasma (P-PRP), leukocyte- and platelet-rich plasma (L-PRP), 
pure platelet-rich fibrin (P-PRF) and leukocyte- and platelet-rich fibrin (L-
PRF).(107)   
De Long et al. proposed the so called “PAW classification”, based on three 
components: the absolute number of platelets (“P”), the manner in which 
platelet activation occurs (“A”) and the presence or absence of white cells 
(“W”).(108) 
Achieving a terminology consensus on platelet concentrates technologies is 
important to avoid confusion in this wide and complex field of research. In 
many articles, the lack of characterization of the tested products made the 
literature in this field very difficult to sort and interpret. Without a consensus, 
this field will remain unclear and this situation will considerably restrain its 
development.  
 
1.2.3. Biological effects 
The advantages of using platelet concentrates in the clinical setting are 
many. The regenerative potential of platelet concentrates on hard and soft 
tissues has been explored considerably during the last two decades. 
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Recently, novel properties have been also pointed out, such as anti-
inflammatory and antimicrobial effects. 
 
1.2.3.1. Hard tissue healing 
Platelet α-granules release many growth factors that may favor bone 
regeneration. Among them there are: platelet-derived growth factor (PDGF), 
transforming growth factor-β (TGF-β), vascular endothelial growth factor 
(VEGF), basic fibroblast growth factor (bFGF), insulin-like growth factor 
(IGF), epidermal growth factor (EGF) and platelet-derived epidermal growth 
factor (PDECGF). These factors are variously involved in stimulating 
chemotaxis, cell proliferation and differentiation (Table).(33) A multitude of 
cytokines and chemokines are also stored and released by α-granules.(69, 
109) 
 
Growth factor Biological activity useful for hard tissue regeneration 
PDGF 
Stimulates proliferation of mesoderm-derived cells such as 
fibroblasts, vascular smooth muscle cells, glial cells and 
chondrocytes. 
Attracts and activates neutrophils, monocytes and fibroblasts. 
Increases the synthesis of phospholipids, cholesterol esters, 
glycogen and prostaglandins. 
Regulates the production and degradation of extracellular matrix 
proteins. 
Stimulates the synthesis of additional growth factors. 
Interacts with TGF-β. 
TGF-β 
Stimulates proliferation of fibroblasts, marrow stem cells and 
preosteoblasts.  
Sustains and amplifies osteoblastic activity during bone healing, as 
target cells are able to synthesize and secrete their own TGF-β to 
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act on themselves or on adjacent cells. 
VEGF Promotes angiogenesis. 
bFGF 
Stimulates proliferation and differentiation of preosteoblasts and 
osteoblasts. 
IGF 
Stimulates proliferation and differentiation of osteoblasts. 
Enhances the synthesis of bone matrix proteins such as alkaline 
phosphatase, osteopontin and osteocalcin. 
EGF May exert a positive activity through its mitogenic characteristics. 
PDECGF Promotes angiogenesis. 
 
1.2.3.2. Soft tissue healing 
Platelets release at the site of injury a variety of substances that are involved 
in all aspects of the wound healing process.(110) Among them there are: 
EGF, PDGF, TGF-a, TGF-b, keratinocyte growth factor (KGF), aFGF, bFGF, 
VEGF, connective tissue growth factor (CTGF) and IGF (Table). For this 
reason, platelet concentrates have been extensively used for topical therapy 
of various clinical conditions, including wounds and soft tissue injuries.(111-
113)   
 
Growth factor Biological activity useful for soft tissue regeneration 
EGF 
Stimulates proliferation of fibroblasts, epidermal and epithelial 
cells. 
Chemoattractant for fibroblasts and epithelial cells.  
Enhances re-epithelialization and angiogenesis.  
Influences the synthesis and turnover of extracellular matrix. 
PDGF 
Stimulates proliferation of fibroblasts, smooth muscle cells, 
chondrocytes, epithelial and endothelial cells. 
Chemoattractant for fibroblasts, muscle cells, hematopoietic and 
mesenchymal cells. 
Stimulates neutrophils and macrophages. 
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Enhances collagen synthesis, collagenase activity and 
angiogenesis. 
TGFα 
Stimulates proliferation of mesenchymal, epithelial and endothelial 
cells. 
Chemoattractant for endothelial cells. 
Controls epidermal development. 
TGFβ 
Enhances collagen synthesis. 
Decreases dermal scarring. 
Inhibits proliferation of fibroblasts, keratinocytes, hematopoietic, 
epithelial and endothelial cells. 
Antagonizes the biological activity of EGF, PDGF, aFGF and 
bFGF. 
KGF 
Most potent growth factor acting on skin keratinocytes. 
Plays a role in tissue repair following skin injuries. 
aFGF 
Stimulates proliferation of skin keratinocytes, dermal fibroblasts 
and vascular endothelial cells. 
bFGF 
Stimulates proliferation of fibroblasts, myoblasts, keratinocytes, 
chondrocytes and endothelial cells. 
Enhances angiogenesis, collagen synthesis, wound contraction, 
matrix synthesis, epithelialization. 
Stimulates KGF production. 
VEGF 
Stimulates proliferation of endothelial cells. 
Induces neovascularisation. 
Stimulates the synthesis of metalloproteinases. 
CTGF Stimulates proliferation and migration of endothelial cells. 
IGF 
Stimulates proliferation of mesodermal cell types. 
Promotes the synthesis of collagenase and prostaglandin E2 in 
fibroblasts. 
Stimulates collagen and matrix synthesis. 
Regulates the metabolism of joint cartilage. 
 
1.2.3.3. Novel properties 
Control of the inflammatory reactions that takes place in a wound can reduce 
pain and enhance the healing process. A reduction of post-surgical 
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inflammation has been reported when using platelet concentrates.(114) 
Several platelet-derived factors may contribute to the anti-inflammatory 
properties of platelet concentrates, such as RANTES and lipoxin A4.(114) 
TGF-β may also exert anti-inflammatory actions. In fact, in an animal model 
of asthma, platelet concentrate lysate rich in TGF-β exhibited 
immunosuppressive and anti-inflammatory properties and enhanced the 
development of FOXP3+ regulatory T cells.(115) Platelet concentrate lysate 
have also shown to counteract the inflammatory effect mediated by IL-1β in 
chondrocytes by inhibiting the activation of nuclear factor-κB, a major 
pathway in the pathogenesis of osteoarthritis.(116, 117) A decrease in the 
expression of cyclooxygenase-2 and CXCR4 target genes was also 
observed. The role played by leukocytes is a matter of intense debate. It is 
possible that they might increase the inflammatory response at the wound 
site because of the metalloproteases and acid hydrolases secreted.(118) 
Further studies are needed to establish a better scientific understanding of 
the anti-inflammatory properties of platelet concentrates. 
Platelet concentrates are also believed to exhibit antibacterial properties, 
thereby potentially limiting the risk of infection of surgical wounds. Recent 
studies have evaluated clinical and in vitro antimicrobial activity of platelet 
concentrates, showing inhibitory effect against various bacteria.(119-132) To 
date, the components responsible for the antimicrobial activity of platelet 
concentrates are poorly understood. Several antimicrobial factors have been 
proposed, including platelet antimicrobial proteins and peptides of the innate 
immune defense, or platelet α-granules components, such as complement 
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and complement-binding proteins.(80, 109, 126, 127, 133-135) Direct 
interaction of platelets with microorganisms, participation in antibody-
dependent cell cytotocity, release of myeloperoxidase, activation of the 
antioxidant responsive element and antigen-specific immune response have 
also been suggested.(125, 136, 137) In fact, platelet concentrates are a 
complex mixture of platelets, leukocytes and plasma, and the respective 
impact of the plasma and cellular components has not been studied in detail 
yet. 
 
1.2.4. Therapeutic applications 
The use of autologous platelet concentrates has gained large popularity in a 
variety of medical fields, which will be briefly discussed in the following 
paragraphs. 
 
1.2.4.1. Dentistry, oral and maxillofacial surgery 
In the field of dentistry, oral and maxillofacial surgery, platelet concentrates 
have been used in different clinical procedures (e.g. sinus floor elevation, 
alveolar ridge augmentation, mandibular reconstruction, maxillary cleft repair, 
treatment of periodontal defects and extraction sockets), where it was applied 
alone or in addition to bone substitutes. Some papers reported positive 
effects of platelet concentrates on bone formation.(138-143) Others reported 
limited or no beneficial effect.(144-148) Currently, there is a lack of scientific 
evidence in the dental literature in favour of or against the clinical use of 
platelet concentrates for bone regeneration. Several reviews about the 
36 
 
application of platelet concentrates in dentistry have been published so 
far.(143, 148-155) Only a few of them followed a systematic approach.(155-
157) Their general conclusion is that several methodological limitations are 
present in the available studies. Future research should focus on strong and 
well-designed randomized controlled clinical trials. 
 
1.2.4.2. Orthopedics and sports medicine 
Reconstruction of anterior cruciate ligament(158), tendon surgery, treatment 
of osteoarthritis, joint injuries and muscle tears are some examples of the 
applications of platelet concentrates in the field of orthopedics and sports 
medicine.(158-161) Ultrasound-guided injection of platelet concentrates may 
offer an alternative treatment over palliative or surgical treatments. Clinical 
benefits of platelet concentrates in this field remain controversial. Studies of 
various levels of evidence have tested their safety and efficacy, but 
standardization of the preparation methods and application procedures is 
necessary for further advancements. The growing emphasis on an evidence-
based approach in the sports medicine and orthopedic settings demands 
additional research efforts before incorporating this technology in routine 
clinical care. 
  
1.2.4.3. Treatment of skin lesions 
Many reports about the application of platelet concentrates on chronic 
wounds are available. Results of clinical studies treating small-sized non-
healing diabetic ulcers with platelet concentrates are encouraging.(162-164) 
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Combination with skin grafting may be required for large, deep ulcers. A 
recent systematic review assessing the effect of platelet concentrates on the 
treatment of cutaneous wounds showed that healing was improved 
compared to control wound care.(165) 
Few reports are also available about the application of platelet concentrates 
on burns, but the value of their use in this field remains unclear. (166-168) A 
definitive assessment will require further studies.(169) 
 
1.2.4.4. Other medical areas 
Platelet concentrates in the form of eye-drops have been successfully used 
in ophthalmology for the treatment of many eye disorders, such as dry eye 
symptoms or corneal perforations.(170-172) 
Platelet concentrates are also applied in plastic surgery and aesthetic 
medicine.(173-175) 
Another interesting approach of this technology is the use of platelet 
concentrates for nerve regeneration purposes.(176, 177) 
Moreover, the pool of growth factors released by platelets has been used as 
a powerful substitute of foetal calf serum in the culture of a wide range of 
cells, including fibroblasts and osteoblasts, mesenchymal stem cells and 
stromal cells.(178-180) 
 
1.2.5. Evidence from our previous work 
Our research group has used P-PRP in the field of dentistry for some years. 
Several clinical studies and systematic reviews of the literature have been 
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performed to evaluate the efficacy and safety of P-PRP in this clinical setting. 
Such studies will be briefly described in the following paragraphs. 
 
1.2.5.1 Systematic reviews of the literature 
In a systematic review, we evaluated the effect of autogenous platelet 
concentrates on the clinical and histomorphometric outcomes of maxillary 
sinus augmentation.(181) Only prospective comparative clinical studies were 
included. No difference in implant survival was found between test and 
control groups. Some studies reported a beneficial effect of platelet 
concentrates based on histomorphometric outcomes, while other studies 
found no significant effect. Favorable effects on soft tissue healing and 
postoperative discomfort reduction were often reported but not quantified. 
In another systematic review, we evaluated the effects of autogenous platelet 
concentrates on clinical outcomes of the surgical treatment of periodontal 
diseases.(182) Only randomized clinical trials were included. A significant 
positive effect of the adjunct of platelet concentrates was found for intrabony 
defects. Such an effect was magnified in studies in which guided tissue 
regeneration (GTR) was not used, whereas in studies using GTR the use of 
platelet concentrates had no adjunctive effect. No significant effect of platelet 
concentrates was found for gingival recession nor for furcation treatment.  
We also systematically assessed if the use of autologous platelet 
concentrates might be beneficial to the healing of extraction sockets.(183)  
Only prospective comparative studies were included. Based on the reports of 
the selected studies, we concluded that the use of platelet concentrates 
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could be beneficial for reducing postoperative pain and inflammation, thereby 
improving quality of life in the early period after extraction. No systematic 
acceleration of osseous healing at the post-extraction site could be 
demonstrated, suggesting that platelet concentrates per se probably exert a 
negligible effect on bone regeneration. 
In conclusion, a clear advantage of platelet concentrates could not be 
evidenced from these reviews. A large heterogeneity was found regarding 
study design, sample size, surgical techniques, grafting materials, methods 
for preparing platelet concentrates and outcome variables. Standardization of 
experimental design is needed in order to detect the true effect of platelet 
concentrates in regenerative procedures in dentistry.  
 
1.2.5.2. Clinical studies 
Three studies showed that P-PRP produced significant beneficial effect to 
patients' quality of life, decreasing pain and surgery side effects as well as 
swelling, after sinus lift and endodontic surgery.(184-186) 
A case report study showed that the addition of P-PRP to anorganic bovine 
bone improved the regenerative process after the surgical treatment of a 
large through-and-through periapical bone lesion.(187) 
A prospective study showed the clinical success of a treatment protocol for 
the rehabilitation of edentulous posterior maxilla consisting of the positioning 
of short implants in combination with transcrestal sinus lifting with the adjunct 
of P-PRP. (188) 
P-PRP was also used in immediate implant placement procedures, 
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demonstrating to be a safe, effective, and predictable treatment option for the 
rehabilitation of fresh post-extraction sockets.(189, 190)  
 
1.3. Aim of this thesis 
The aim of this thesis was to evaluate the antimicrobial activity of P-PRP. In 
particular, we assessed whether P-PRP displayed an inhibitory activity 
against microorganisms colonizing the oral cavity such as Enterococcus 
faecalis, Candida albicans, Streptococcus agalactiae, Streptococcus oralis 
and Pseudomonas aeruginosa. We also evaluated the effect of platelet 
concentration, of the activation step and of the presence of plasmatic 
components on the antimicrobial activity of P-PRP against Enterococcus 
faecalis, Streptococcus agalactiae and Streptococcus oralis. 
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2. MATERIALS AND METHODS 
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2.1. Donors 
Blood samples were obtained from 47 healthy donors. All subjects were in 
general good health (ASA 1-2 according to the American Society of 
Anaesthesiologists classification) and older than 18 years. No patient took 
antibiotics during the month before surgery, nor was under anticoagulant or 
immunosuppressive therapy. Written informed consent for participation in the 
study was obtained from all patients. The present research was performed 
within the guidelines of the Helsinki Declaration for biomedical research 
involving human subjects. The study was approved by the Review Board of 
the Galeazzi Orthopedic Institute. 
 
2.2. Blood collection 
Peripheral blood from each donor (about 4,5 ml) was taken by venipuncture 
into 5 ml sterile tubes (Vacutainer, BD, Franklin Lakes, New Jersey, U.S.A) 
containing 3,8% (wt/vol) trisodium citrate as anticoagulant. Tubes were 
immediately gently inverted three times, as clotting may occur when the 
blood is not thoroughly mixed with the anticoagulant additive. Tubes were 
inverted gently to prevent hemolysis. 
 
2.3. Production of pure platelet-rich plasma (P-PRP) 
 
2.3.1. Production of single donor P-PRP  
Fresh human whole blood from 17 donors was processed using a laboratory 
centrifuge (Megafuge 1.0 R, Heraeus, Hanau, Germany) to obtain P-PRP, 
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following Anitua’s protocol.(191) Peripheral blood (4,5 ml) from each donor 
was centrifuged at 460 g for 8 min at room temperature. After centrifugation, 3 
components were obtained: red blood cells at the bottom of the tube; a thin 
layer of leukocytes referred to as “buffy coat” in the middle; and plasma, 
which contains most of the platelets, at the top. The 1 ml plasma fraction 
located above the red cell fraction, but not including the buffy coat, was 
collected. Care was taken to avoid creating any turbulence and to prevent the 
aspiration of leukocytes and erythrocytes. The remaining plasma was 
discarded. P-PRP was stored at -20°C until use. 
 
2.3.2. Production of pooled donor P-PRP  
Fresh human whole blood from donors was processed using a laboratory 
centrifuge (Megafuge® 1.0 R, Heraeus, Hanau, Germany) to obtain P-PRP, 
following Anitua’s protocol.(191) Four pools of blood were produced: two 
pools (one of 16 ml and the other of 72 ml) were created with blood collected 
from 22 patients with the baseline platelet count falling into the physiological 
range (150.000-400.000 platelets/μl), while two pools (each of 16 ml) were 
created with blood collected from 8 patients with the baseline platelet count 
above (4 patients) or below (4 patients) the physiological range, respectively. 
Pooled blood was transferred into 9 ml tubes and centrifuged at 580 g for 8 
min at room temperature. After centrifugation, three components were 
obtained: red blood cells, a thin layer of leukocytes referred to as “buffy coat” 
and plasma. The 2 ml plasma fraction located above the red cell fraction, but 
not including the buffy coat, was collected. Care was taken to avoid creating 
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any turbulence and to prevent the aspiration of leukocytes and erythrocytes. 
P-PRP was stored at -20°C until use. 
 
2.4. Production of platelet-poor plasma (PPP) 
To prepare PPP, an aliquot of 2 ml was collected from the P-PRP obtained 
from the 16 ml blood pools and centrifuged at 3000 g for 10 minutes in 
Megafuge 1.0 R (Heraeus Holding, Hanau, Germany). The supernatant 
(almost 2 ml) was recovered. The platelet pellet (PLT) was resuspended in 2 
ml of phosphate buffered saline (PBS; Sigma-Aldrich, St. Louis, Missouri, 
U.S.A.). In this way, a pure platelet solution without plasmatic components 
was obtained. PPP and PLT were stored at -20°C until use. 
 
2.5. Production of 2-fold and 4-fold concentrated PRP (PRPx2, PRPx4) 
To further increase platelet concentration, an aliquot of 16 ml was collected 
from the P-PRP produced from the 72 ml blood pool and centrifuged at 3000 
g for 10 minutes in Megafuge 1.0 R (Heraeus Holding, Hanau, Germany). 
The supernatant (about 16 ml) was recovered, and the platelet pellet was 
resuspended in half of the starting plasma volume in order to obtain a platelet 
concentration two times higher than that of P-PRP (PRPx2). The procedure 
was repeated twice in order to produce a platelet concentration four times 
higher than that of P-PRP (PRPx4) (Figure 9). PRPx2 and PRPx4 were 
stored at -20°C until use. 
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Figure 9. Experimental design of the study. The image illustrates the 
procedure used to obtain P-PRP, PPP, PLT, PRPx2 and PRPx4 from whole 
blood. 
 
2.6. Determination of platelet and leukocyte count 
46 
 
Platelet concentration in whole blood, P-PRP, PPP, PRPx2 and PRPx4 was 
counted automatically using a hematology analyzer (XE-2100, Sysmex 
Europe, Norderstedt, Germany). To evaluate the purity of P-PRP, white blood 
cells count was also performed both in whole blood and P-PRP. According to 
Anitua et al., leukocyte levels in P-PRP are consistently lower than in whole 
blood (< 103 white blood cells/µl).(191) 
 
2.7. Activation of coagulation 
P-PRP, PPP, PLT, PRPx2 and PRPx4 were activated shortly before use. In 
order to initiate clotting and trigger the release of platelet content, the 
activator, consisting of 10% CaCl2 (BTI, Vitoria, Alava, Spain) was added (50 
μl per ml). 
 
2.8. Microbial strains 
Microbial strains previously isolated from clinical samples were used. In 
particular, five representative microorganisms chosen among those 
colonizing the oral cavity were used: three aerobic gram-positive bacteria 
such as Enterococcus faecalis, Streptococcus agalactiae and Streptococcus 
oralis; one aerobic gram-negative bacteria such as Pseudomonas 
aeruginosa; and one yeast such as Candida albicans. This strains were 
previously identified by biochemical identification (API system and Vitek 2 
Compact (bioMériéux, Marcy l'Etoile, France)) and confirmed by DNA 
sequencing of 80 bp of the variable regions V1 and V3 of the 16S rRNA gene 
by pyrosequencing (PSQ96RA, Diatech, Jesi, Italy). For each species, five 
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strains were used. Each strain presented different characteristics (e.g. 
different antibiotic resistance). In addition, ATCC strains were used as 
controls: E. faecalis ATCC #29212, C. albicans ATCC #928, S. agalactiae 
ATCC #13813, S. oralis ATCC #35037 and P. aeruginosa ATCC #27853. 
 
2.9. Microbial cultures 
Microbial strains were kept stored in cryoprotectant medium (brain-heart 
infusion broth (BHI; bioMériéux, Marcy l'Etoile, France) with 10-15% glycerol 
(Sigma-Aldrich, St. Louis, Missouri, U.S.A.)) at -80°C to suspend metabolism. 
Before use, microbial cultures were recovered by thawing and seeding on 
appropriate solid medium. E. faecalis and P. aeruginosa were seeded on 
Trypticase Soy Agar (bioMériéux, Marcy l'Etoile, France) and incubated for 
24 hours at 37°C. C. albicans was seeded on Sabouraud Glucose Agar 
(bioMériéux, Marcy l'Etoile, France) for 24 hours at 37°C. S. agalactiae and 
S. oralis were seeded on Columbia Blood Agar (bioMériéux, Marcy l'Etoile, 
France) and incubated in a 5% CO2 atmosphere for 24 hours at 37°C. 
 
2.10. Determination of antimicrobial activity 
 
2.10.1. Determination of the minimum inhibitory concentration (MIC) 
The MIC, defined as the lowest concentration of an antimicrobial substance 
that inhibits the visible growth of a microorganism, was determined by broth 
microdilution method (Figure 10). A suspension in BHI (or BHI + 5% blood for 
S. agalactiae and S. oralis) was prepared for each strain, with an optical 
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density equal to 0,5 McFarland (1x108CFU/ml). After obtaining a 
concentration of 1x104 CFU/ml using appropriate dilutions, 20 μl of each 
suspension were inoculated in a 96-wells microplate containing 180 μl of BHI 
(or BHI + 5% blood for S. agalactiae and S. oralis) and a serial dilution of the 
material under evaluation. Positive controls were performed inoculating the 
microbial suspension in BHI (or BHI + 5% blood for S. agalactiae and S. 
oralis) alone. For pooled donor P-PRP, PPP, PLT, PRPx2 and PRPx4, non 
activated samples (that is, CaCl2 was not added) were also tested. In order to 
assess that CaCl2 did not possess antimicrobial activity per se, controls were 
performed inoculating microbial suspension in BHI (or BHI + 5% blood for S. 
agalactiae and S. oralis) + CaCl2. MIC values were read after incubation for 
24 hours at 37°C (in a 5% CO2 atmosphere for S. agalactiae and S. oralis). 
Assays were performed in duplicate for each strain and, if the two MICs 
differed by more than two wells, the assay was repeated. MIC values were 
expressed as platelet concentration (n° platelets/µl) and dilution (%). 
 
 
Figure 10. Schematic representation of a MIC test. The image illustrates 
the row of a 96-well microplate. Numbers in each well represents the ratio 
between antimicrobial substance and culture medium. In the first well, 
antimicrobial substance and culture medium are mixed in 1:1 ratio. A serial 
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dilution is performed until the last well, in which only culture medium is 
present (positive control of growth). Microbial suspension is then inoculated 
in each well. The MIC corresponds to the dilution present in the last well in 
which microbial growth is observable (colored in orange) after incubation for 
24 hours in appropriate culture conditions. 
 
2.10.2. Determination of the minimum microbicidal concentration (MMC) 
The MMC, defined as the lowest concentration of an antimicrobial substance 
that kills a microorganism, was determined. MMC test involves a series of 
steps that that place once MIC test is performed. Samples (20 μl) of microbial 
suspension were collected from each well of the plate used for the MIC assay 
and subcultured on appropriate solid medium (Figure 11). Trypticase Soy 
Agar (bioMériéux, Marcy l'Etoile, France) was used for E. faecalis and P. 
aeruginosa; Sabouraud Glucose Agar (bioMériéux, Marcy l'Etoile, France) 
was used for C. albicans; and Columbia Blood Agar (bioMériéux, Marcy 
l'Etoile, France) was used for S. agalactiae and S. oralis. MBC value were 
read after incubation for 24 hours at 37°C (in a 5% CO2 atmosphere for S. 
agalactiae and S. oralis). 
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Figure 11. Schematic representation of an MMC test. The image 
illustrates the row of a 96-well microplate in which a MIC test has been 
performed. A sample of microbial suspension from each well (numbers from 1 
to 12) is inoculated onto an agar plate. The MMC corresponds to the dilution 
present in the last well that permits the growth of microbial subcultures 
(orange circles) after incubation for 24 hours in appropriate culture 
conditions. 
 
2.11. Statistical Analysis 
Results were expressed as means ± standard deviations. When two groups 
were compared, an analysis was done using unpaired t test. For data in 
which there were more than two comparisons, an analysis was done using 
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one-way ANOVA followed by Bonferroni’s post-test. A probability value of P = 
0,05 was used as the significance level. Data analysis was performed using a 
statistical software package (GraphPad Prism, GraphPad Software Inc., La 
Jolla, California, U.S.A.). 
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3. RESULTS 
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3.1. Platelet and leukocyte count 
 
3.1.1. Platelet and leukocyte count in single donor P-PRP 
Mean platelet and leukocyte concentrations in whole blood were (239.000 ± 
77.000)/μl and (6.400 ± 2.300)/μl, respectively. Mean platelet and leukocyte 
concentrations in P-PRP were (350.000 ± 120.000)/μl and (340 ± 270)/μl, 
respectively. Platelets were 1,5 times more concentrated in P-PRP than in 
whole blood, while leukocytes were 18,8 times less concentrated. 
 
3.1.2. Platelet and leukocyte count  in pooled donor P-PRP, PPP, PRPx2 
and PRPx4 
Platelet concentrations in whole blood, P-PRP, PPP, PRPx2 and PRPx4 are 
shown in Table 3. Platelet concentration in P-PRP was 1,5 to 2,2 times higher 
than in whole blood. PRPx2 and PRPx4 were 1,5 and 3,1 times more 
concentrated than P-PRP, respectively. 
Mean leukocyte concentrations in whole blood and P-PRP were (7500 ± 
3200)/μl and (802 ± 123)/μl, respectively. White blood cells in P-PRP were 
9,4 times less concentrated than in whole blood. The percentages of the five 
types of leukocytes (neutrophils, lymphocytes, monocytes, eosynophils and 
basophils) in P-PRP differed from percentages in whole blood (Table 4). In 
particular, white blood cells in P-PRP consisted mainly of lymphocytes (72%), 
while neutrophils were the most abundant leukocyte type in whole blood 
(62,3%). 
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 Pool 1 Pool 2 Pool 3 Pool 4 
Blood 184.000 252.000 535.000 149.000 
P-PRP 328.000 565.000 787.000 227.000 
PPP 15.000 / 14.000 11.000 
PRPx2 / 825.000 / / 
PRPx4 / 1.768.000 / / 
 
Table 3. Platelet count in pooled donor P-PRP, PPP, PRPx2 and PRPx4. 
Concentrations are expressed as n°platelets/µl. Slashes indicate that the 
count was not performed. 
 
 Blood P-PRP 
 Mean SD Mean SD 
Neutrophils 62,3 3,8 18,7 13,1 
Lymphocytes 25,9 2,7 72,0 13,0 
Monocytes 9,3 1,1 8,4 1,4 
Eosinophils 2,1 0,4 0,8 0,4 
Basophils 0,4 0,1 0,2 0,1 
 
Table 4. Leukocyte count in pooled donor P-PRP. Concentrations are 
expressed as percentages (%). SD = standard deviation. 
 
3.2. Antimicrobial activity of single donor P-PRP 
MIC are shown in Figure 12. For each microorganism, results were 
expressed as the mean of the MIC calculated for 5 clinical strains and one 
ATCC strain. As can be seen from the figure, MIC were fairly uniform among 
microorganisms, except for C. albicans, whose MIC was about 4 times higher 
than the others. E. faecalis, S. agalactiae and S. oralis were inhibited by a 
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platelet concentration of about 20.000 platelets/µl (corresponding to a dilution 
of about 10% from the initial concentration), while C. albicans was inhibited 
by a platelet concentration of about 80.000 platelets/µl (corresponding to a 
dilution of about 40% from the initial concentration). The difference among 
effective concentrations was statistically significant (P value < 0,001). 
P. aeruginosa is not depicted in figure because it was not inhibited by P-PRP 
at the platelet concentrations tested. 
The MMC for E. faecalis, S. agalactiae and S. oralis was 3-4 times higher 
than the MIC. In contrast, the MMC of C. albicans  couldn’t be estimated at 
the platelet concentrations tested (Figure 13). 
 
 
Figure 12. MIC of P-PRP. Error bars represent standard deviations. *P value 
< 0,001. 
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Figure 13. MMC of P-PRP. Exemplificative photograph of an agar plate on 
which was performed the MMC test for C. albicans (left) and E. faecalis 
(right). As can be seen from the figure, E. faecalis was more susceptible to P-
PRP effect than C. albicans. 
 
3.3. Antimicrobial activity of pooled donor P-PRP 
 
3.3.1. Comparison among P-PRP, PPP and PLT 
MIC of P-PRP and PPP are shown in Figure 14. For each microorganism, 
results were expressed as the mean of the MIC calculated for 5 clinical 
strains and one ATCC strain. As concentration of P-PRP and PPP expressed 
as n°platelets/µl is substantially different, MIC was expressed as dilution (%) 
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from the initial concentration. As can be seen from the figure, P-PRP and 
PPP were effective in inhibiting the growth of all bacterial strains tested at a 
dilution of about 15% (corresponding to a concentration of about 40.000 
platelets/µl for P-PRP and 2.000 platelets/µl for PPP). Differences between 
effective concentrations were not statistically significant (P = 0,47 for E. 
faecalis, P = 0,57 for S. agalactiae, P = 0,84 for S. oralis). PLT alone did not 
show any antibacterial activity and then was not depicted in figure 14. 
Moreover, only CaCl2-activated samples were able to inhibit bacterial growth. 
CaCl2 per se alone did not show any antibacterial activity. 
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Figure 14. MIC of P-PRP vs. PPP. Error bars represent standard deviations. 
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3.3.2. Comparison between P-PRP and PPP from donors with different 
baseline platelet count  
MIC of P-PRP and PPP obtained from patients with different baseline platelet 
count are shown in Figure 15. For each microorganism, results were 
expressed as the mean of the MIC calculated for 5 clinical strains and one 
ATCC strain. As concentration of P-PRP and PPP expressed as n°platelets/µl 
is not comparable due to a substantial difference, MIC was expressed as 
dilution (%) from the initial concentration. As can be seen from the figure, P-
PRP and PPP were effective in inhibiting the growth of all bacterial strains 
tested, independent of baseline platelet concentration. The effective dilution 
of P-PRP and PPP was about 15% (corresponding to a concentration of 
about 90.000 and 2.000 platelets/µl for P-PRP and PPP from donors with 
baseline platelet count > 400.000 platelets/µl, and to 20.000 and 1.000 
platelets/µl for P-PRP and PPP from donors with baseline platelet count < 
150.000 platelets/µl, respectively) for all strains. Differences between 
effective concentrations were not statistically significant (P = 0,85 for E. 
faecalis, P = 0,13 for S. agalactiae, P = 0,99 for S. oralis). As seen before, 
only CaCl2-activated samples were able to inhibit bacterial growth. CaCl2 per 
se alone did not show any antibacterial activity. 
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Figure 15. MIC of P-PRP vs. PPP from donors with different baseline 
platelet count. Error bars represent standard deviations. High = baseline 
platelet count > 400.000/µl. Low = baseline platelet count < 150.000/µl. 
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3.3.3. Comparison among P-PRP, PRPx2 and PRPx4 
MIC of P-PRP, PRPx2 and PRPx4 are shown in Figure 16. For each 
microorganism, results were expressed as the mean of the MIC calculated 
for 5 clinical strains and one ATCC strain. As concentration of P-PRP, PRPx2 
and PRPx4 expressed as n°platelets/µl were substantially different, MIC was 
expressed as dilution (%) from the initial concentration. As can be seen from 
the figure, P-PRP, PRPx2 and PRPx4 were effective in inhibiting the growth 
of all bacterial strains tested. The effective dilution of P-PRP, PRPx2 and 
PRPx4 was about 15% (corresponding to a concentration of about 50.000, 
100.000 and 200.000 platelets/µl for P-PRP, PRPx2 and PRPx4, 
respectively) for all strains. Differences between effective concentrations 
were not statistically significant (P = 0,71 for E. faecalis, P = 0,87 for S. 
agalactiae, P = 0,62 for S. oralis). As seen before, only CaCl2-activated 
samples were able to inhibit bacterial growth. CaCl2 per se alone did not 
show any antibacterial activity. 
62 
 
 
Figure 16. MIC of P-PRP vs. PRPx2 vs. PRPx4. Error bars represent 
standard deviations. 
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4.DISCUSSION 
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The regenerative potential of platelet concentrates has been explored 
considerably during the last two decades. On the contrary, in the available 
literature only few reports can be found about their antimicrobial effects. To 
date, the components responsible for the antimicrobial activity of platelet 
concentrates remain poorly understood, in particular because these materials 
are a complex mixture of platelets, white blood cells and plasma. The 
respective impact of the plasma and cellular components has not been 
studied in detail yet. Several antimicrobial factors have been proposed, 
including platelet antimicrobial proteins and peptides of the innate immune 
defense, or platelet α-granules components, such as complement and 
complement-binding proteins.(80, 109, 127, 133-135) Direct interaction of 
platelets with microorganisms and participation in antibody-dependent cell 
cytotocity and white blood cells in direct bacterial killing, release of 
myeloperoxidases, activation of the antioxidant responsive element and 
antigen-specific immune response have also been suggested.(125, 136, 137) 
The role of leucocytes within platelet concentrates is a matter of intense 
debate. Some authors have suggested that inclusion of white blood cells in 
platelet concentrates may help to improve the stability of the scaffold and 
increase the antimicrobial potential.(107) However, Anitua et al. results 
showed that the addition of leukocyte fraction did not significantly improve the 
antimicrobial properties of P-PRP.(191) It is also possible that the additional 
leukocyte content might increase the inflammatory response at the site 
because of the metalloproteases, pro-inflammatory proteases and acid 
hydrolases secreted by white blood cells.(192) 
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The first part of this study has shown that P-PRP was active against some of 
the microorganisms isolated from the oral cavity such as E. faecalis, C. 
albicans, S. agalactiae and S. oralis, but not against P. aeruginosa. Except 
for E. faecalis and P. aeruginosa, platelet concentrates have never been 
tested against such microorganisms. 
E. faecalis is associated with different forms of periradicular disease, 
including primary extraradicular and post-treatment persistent 
infections.(193) Such microorganism possesses the ability to survive the 
effects of root canal treatment and persists as a pathogen in the root canals 
and dentinal tubules of teeth. Implementing methods to effectively eliminate 
E. faecalis from the dental apparatus is a challenge. We found that P-PRP 
was active at low platelet concentration ranges (1-2 orders of magnitude 
lower than the baseline blood values) against this microorganism, while 
Bielecki et al.  observed no activity of platelet concentrate.(121) The reasons 
for this discrepancy may lie in the different protocol used for platelet 
concentrate production, which can lead to products with different biological 
characteristics, or in the different sensibility of the method (Kirby-Bauer disc-
diffusion method) used to evaluate the susceptibility to platelet concentrate. 
Oral candidosis is the most common fungal infection encountered in general 
dental practice. It manifests in a variety of clinical presentations and can 
occasionally be refractory to treatment. It is caused by commensal Candida 
species. While a large majority of healthy individuals harbor strains of 
Candida intraorally, only selected groups of individuals develop oral 
candidosis. The most commonly implicated species is C. albicans, which is 
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isolated in over 80% of oral candidal lesions.(194) In the present study, we 
observed that P-PRP was active against C. albicans at higher platelet 
concentration ranges (same order of magnitude of the baseline blood values) 
than those effective against the other bacteria tested. This result is consistent 
with the findings of Tang et al. who tested in vitro antimicrobial activity of 
seven antimicrobial peptides isolated from human platelets, and noticed that 
they were more potent against bacteria than fungi.(80)  
Streptococcus strains are consistently present in the human oral cavity and 
are the major early colonizers of dental biofilm. Strains of many species of 
oral streptococci are generally commensal in humans. However, strains of 
other species, including those of S. oralis and S. agalactiae, may be more 
commonly associated with significant infections.(195, 196) In this study, we 
observed that P-PRP was active against S. agalactiae and S. oralis at 
platelet concentration ranges similar to the range which inhibited E. faecalis.  
P. aeruginosa is an opportunistic bacterial pathogen that has been shown to 
integrate into oral biofilms.(197) Its presence has been associated with the 
onset of ventilator-associated pneumonia.(198) We found no activity of P-
PRP against P. aeruginosa at the concentrations used in this experiment. 
This result is in line with the findings of Bielecki et al. and Burnouf et al., who 
even observed that platelet concentrate induced growth of this 
microorganism, suggesting that platelet concentrate may induce a flare-up of 
infection from P. aeruginosa.(121, 122) The value of platelet concentrates in 
the presence of a co-existing infection with this bacterium is therefore 
uncertain. 
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In our study we also used standard ATCC bacterial strains, which may 
behave in a way different from isolates, in order to assure reliability of results 
and reproducibility of experimentation. Results were similar to those obtained 
with clinical isolates of bacteria. 
In addition, we performed a MMC test. We found such test difficult to 
perform, as P-PRP coagulates at high concentrations. MMC values couldn’t 
be obtained for C. albicans, while MMC values for the other microorganisms 
were 3-4 times higher than MIC values. Further studies are necessary to 
investigate the true potential bactericidal effect of P-PRP. 
The second part of this study was designed to elucidate which components 
of P-PRP can inhibit bacteria. We tested 1) P-PRP, which is the formulation 
commonly used in dentistry and oral surgery 2) PLTs resuspended in PBS, in 
order to determine the role of platelets isolated from the plasmatic 
components, and 3) PPP in order to deﬁne the antimicrobial role of plasma 
innate or humoral immune response. 
Moreover, we tested the above-mentioned products before and after 
activation with CaCl2, in order to evaluate their antimicrobial activity in the 
absence of activation of coagulation and release of platelets granules 
content. 
Products were tested against E. faecalis, S. agalactiae and S. oralis, which 
have been shown to be susceptible to P-PRP activity in the first part of this 
study. All materials were prepared from the same pool of donors to limit the 
impact of individual donor variations. CaCl2-activated P-PRP inhibited all 
strains, conﬁrming the observations made in the first part of this study. Also 
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CaCl2-activated PPP exerted a comparable antibacterial activity against all 
strains tested. By contrast, PLTs alone did not show any antibacterial activity. 
These data seems to suggest that the antimicrobial activity against E. 
faecalis, S. agalactiae and S. oralis is sustained by plasma components 
rather than platelet-derived factors. Another study tried to further understand 
which plasma components might bear the antimicrobial activity, testing 
samples after heat complement inactivation.(122) The absence of any 
bacterial inhibition by any of the heat-treated plasma and platelet materials 
supported the idea that the plasma complement (and/or other heat-sensitive 
compounds) played the major role in the bacteriostatic properties of 
concentrates. 
Moreover, we observed that only CaCl2-activated materials were able to 
inhibit bacterial growth, suggesting that the activation of coagulation is a 
fundamental step. 
We also evaluated the effect of platelet concentration on the antimicrobial 
activity of platelet concentrate, comparing the activity of P-PRP and PPP 
obtained from a pool of patients having the baseline platelet count higher or 
lower than the physiological range. Sex and age were not significantly 
different between the two groups so as to reduce variability due to donor’s 
individual features. As seen before, results showed that CaCl2-activated P-
PRP and PPP had a similar antibacterial activity against all bacteria tested, 
independent of the baseline platelet concentration. 
Moreover, we compared CaCl2-activated P-PRP, PRPx2 and PRPx4. All 
products were prepared from the same pool of donors to limit the impact of 
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individual donor variations. We observed that all of them had a similar 
antibacterial activity against the strains tested, independent of their platelet 
concentration. These results are consistent with the findings of previous 
studies showing no correlation between antimicrobial activity and the 
concentration of platelets in the blood and PRP.(121, 191)  
Bacterial infection is one of the most serious complications impairing wound 
healing and tissue regeneration. Even when applying strict disinfection, 
bacteria can infiltrate and colonize the underlying tissues of the wound. The 
combination of proteolytic enzymes, toxin-rich bacterial exudates and chronic 
inflammation can alter growth factors and metalloproteinases, thereby 
affecting the cellular machinery needed for cell proliferation and wound 
healing.(199, 200) Developing approaches and strategies that may help to 
control or prevent the problem of wound infections would have considerable 
clinical, social and economic effects. 
In addition to its established regenerative properties, in this study P-PRP 
demonstrated to possess also an antibacterial activity. Therefore P-PRP 
could be a potentially useful substance in the fight against postoperative 
infections and might represent the linking of osteoinductive and antimicrobial 
activity. The findings of the second part of this study may also have practical 
implications in the modality of application of P-PRP. In particular, it would be 
interesting to determine whether applications of the platelet-poor fraction on a 
wound, after the initial application of the platelet-rich fraction that enhance 
healing, may limit the risk of bacterial infection. Further research should 
investigate P-PRP antimicrobial capacity compared to antibiotics, its exact 
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antibacterial spectrum and prove its efficacy in the in vivo situation. The 
influence of patients’ characteristics (sex, age, blood parameters like 
hematocrit, plasma proteins, platelet count, drug assumption, etc…) on 
antimicrobial activity should be also clarified. 
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